Coologics raises $3 million Seed Round to advance women’s health innovation

Cleveland-based Coologics has closed an oversubscribed $3 million+ seed round—doubling its original $1.5 million target. The clinical-stage medical device company is developing Vlisse, a drug-free intravaginal cooling device for the treatment of vaginal infections, including bacterial vaginosis and yeast infections.

Why it matters

More than 6.5 million women in the U.S. suffer from non-healing vaginal infections, contributing to $50 billion in healthcare costs annually. Coologics is taking aim at this widespread but underserved medical issue with a technology that could reduce antibiotic dependence and improve patient outcomes.

About the raise

The round was led by Prevail and Dream Ventures, with notable participation from two university alumni groups: Ohio State Early Investor Network and Illinois Ventures’ Illini Angels Program. Coologics was co-founded by Dr. Kim Langdon (CEO, Ohio State alum) and Dr. Nicole Williams (CMO, Illinois alum).

“The overwhelming interest in our seed round validates the critical need for a more effective treatment for vaginal infections,” said Dr. Langdon.

What’s next

The funding will help Coologics complete its ongoing clinical trial, submit for FDA review, and begin initial market rollout. The company is targeting its first product launch with Vlisse, a patented cooling-based device offering a drug-free alternative to antifungal treatments.

This seed round follows growing momentum across Ohio’s startup and HealthTech ecosystem, with Coologics joining a wave of companies advancing women’s health innovations from pre-seed through commercialization.